I Kurilova1,2, A Bendet1, E K Fung3, E N Petre1, J L Humm3, F E Boas1, C H Crane4, N Kemeny5, T P Kingham6, A Cercek5, M I D'Angelica6, R G H Beets-Tan2, C T Sofocleous7. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Department of Radiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 5. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 6. Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 7. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. sofoclec@mskcc.org.
Abstract
PURPOSE: To evaluate safety and efficacy of radiation segmentectomy (RS) with 90Y glass microspheres in patients with limited metastatic liver disease not amenable to resection or percutaneous ablation. METHODS: Patients with ≤ 3 tumors treated with RS from 6/2015 to 12/2017 were included. Target tumor radiation dose was > 190 Gy based on medical internal radiation dose (MIRD) dosimetry. Tumor response, local tumor progression (LTP), LTP-free survival (LTPFS) and disease progression rate in the treated segment were defined using Choi and RECIST 1.1 criteria. Toxicities were evaluated using modified SIR criteria. RESULTS: Ten patients with 14 tumors underwent 12 RS. Median tumor size was 3 cm (range 1.4-5.6). Median follow-up was 17.8 months (range 1.6-37.3). Response rates per Choi and RECIST 1.1 criteria were 8/8 (100%) and 4/9 (44%), respectively. Overall LTP rate was 3/14 (21%) during the study period. One-, two- and three-year LTPFS was 83%, 83% and 69%, respectively. Median LTPFS was not reached. Disease progression rate in the treated segment was 6/18 (33%). Median overall survival was 41.5 months (IQR 16.7-41.5). Median delivered tumor radiation dose was 293 Gy (range 163-1303). One major complication was recorded in a patient post-Whipple procedure who suffered anaphylactic reaction to prophylactic cefotetan and liver abscess in RS region 6.5 months post-RS. All patients were alive on last follow-up. CONCLUSION: RS of ≤ 3 hepatic segments can safely provide a 2-year local tumor control rate of 83% in selected patients with limited metastatic liver disease and limited treatment options. Optimal dosimetry methodology requires further investigation.
PURPOSE: To evaluate safety and efficacy of radiation segmentectomy (RS) with 90Y glass microspheres in patients with limited metastatic liver disease not amenable to resection or percutaneous ablation. METHODS: Patients with ≤ 3 tumors treated with RS from 6/2015 to 12/2017 were included. Target tumor radiation dose was > 190 Gy based on medical internal radiation dose (MIRD) dosimetry. Tumor response, local tumor progression (LTP), LTP-free survival (LTPFS) and disease progression rate in the treated segment were defined using Choi and RECIST 1.1 criteria. Toxicities were evaluated using modified SIR criteria. RESULTS: Ten patients with 14 tumors underwent 12 RS. Median tumor size was 3 cm (range 1.4-5.6). Median follow-up was 17.8 months (range 1.6-37.3). Response rates per Choi and RECIST 1.1 criteria were 8/8 (100%) and 4/9 (44%), respectively. Overall LTP rate was 3/14 (21%) during the study period. One-, two- and three-year LTPFS was 83%, 83% and 69%, respectively. Median LTPFS was not reached. Disease progression rate in the treated segment was 6/18 (33%). Median overall survival was 41.5 months (IQR 16.7-41.5). Median delivered tumor radiation dose was 293 Gy (range 163-1303). One major complication was recorded in a patient post-Whipple procedure who suffered anaphylactic reaction to prophylactic cefotetan and liver abscess in RS region 6.5 months post-RS. All patients were alive on last follow-up. CONCLUSION: RS of ≤ 3 hepatic segments can safely provide a 2-year local tumor control rate of 83% in selected patients with limited metastatic liver disease and limited treatment options. Optimal dosimetry methodology requires further investigation.
Authors: Steven Y Huang; Asher Philip; Michael D Richter; Sanjay Gupta; Mark L Lessne; Charles Y Kim Journal: Semin Intervent Radiol Date: 2015-06 Impact factor: 1.513
Authors: Derek M Biederman; Joseph J Titano; Ricki A Korff; Aaron M Fischman; Rahul S Patel; Francis S Nowakowski; Robert A Lookstein; Edward Kim Journal: J Vasc Interv Radiol Date: 2017-11-21 Impact factor: 3.464
Authors: Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem Journal: Radiology Date: 2018-04-24 Impact factor: 11.105
Authors: John M Creasy; Eran Sadot; Bas Groot Koerkamp; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Vinod P Balachandran; T Peter Kingham; Ronald P DeMatteo; Peter J Allen; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica Journal: Surgery Date: 2018-02-15 Impact factor: 3.982
Authors: Michael Vouche; Ali Habib; Thomas J Ward; Edward Kim; Laura Kulik; Daniel Ganger; Mary Mulcahy; Talia Baker; Michael Abecassis; Kent T Sato; Juan-Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Elias Hohlastos; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425
Authors: Siddharth A Padia; Sharon W Kwan; Bahman Roudsari; Wayne L Monsky; Andrew Coveler; William P Harris Journal: J Vasc Interv Radiol Date: 2014-05-14 Impact factor: 3.464
Authors: Theo Ruers; Frits Van Coevorden; Cornelis J A Punt; Jean-Pierre E N Pierie; Inne Borel-Rinkes; Jonathan A Ledermann; Graeme Poston; Wolf Bechstein; Marie-Ange Lentz; Murielle Mauer; Gunnar Folprecht; Eric Van Cutsem; Michel Ducreux; Bernard Nordlinger Journal: J Natl Cancer Inst Date: 2017-09-01 Impact factor: 11.816